8-K filing — Bicara Therapeutics Inc. (BCAX)
Filed: 2026-08-25 AccNo: 0001628280-26-058937 Size: 319 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
Bicara Therapeutics (BCAX) reported a narrower-than-expected loss in Q2. Analysts raised price targets, but shares dipped 14.3% to $23.76. #BCAX #earnings
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 12, 2026, 12:34 PM
- Checked
- Aug 12, 2026, 12:34 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
BMO Capital Initiates Coverage On Bicara Therapeutics with Outperform Rating, Announces Price Target of $35
BMO Capital analyst David Lebowitz initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Outperform rating and announces Price Target of $35.
Read original at benzingaGoldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $20
Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $18 to $20.
Read original at benzingaWedbush Maintains Outperform on Bicara Therapeutics, Raises Price Target to $33
Wedbush analyst David Nierengarten maintains Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and raises the price target from $30 to $33.
Read original at benzinga